Via Pharmaceuticals Valuation
| VIAP Stock | USD 0.0005 0.00 0.00% |
Via Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Via Pharmaceuticals from inspecting the company fundamentals such as Number Of Shares Shorted of 10.27 K, price to book of 1.89 X, and Return On Asset of -2.42 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Via Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Via Pharmaceuticals is based on 3 months time horizon. Increasing Via Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Via Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 0.0005, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.0E-4 | Real 4.2E-4 | Hype 5.0E-4 | Naive 5.0E-4 |
The intrinsic value of Via Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Via Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Via Pharmaceuticals helps investors to forecast how Via stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Via Pharmaceuticals more accurately as focusing exclusively on Via Pharmaceuticals' fundamentals will not take into account other important factors: About Via Pharmaceuticals Valuation
The stock valuation mechanism determines Via Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Via Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Via Pharmaceuticals. We calculate exposure to Via Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Via Pharmaceuticals's related companies.VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. The company was founded in 2004 and is headquartered in San Francisco, California. Via Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.
Additional Tools for Via Stock Analysis
When running Via Pharmaceuticals' price analysis, check to measure Via Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Via Pharmaceuticals is operating at the current time. Most of Via Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Via Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Via Pharmaceuticals' price. Additionally, you may evaluate how the addition of Via Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.